The RNA-binding protein Ataxin-2 binds to and stabilizes numerous mRNA sequences, together with that of the transactive response DNA binding protein 43 kDa (TDP-43). Ataxin-2 is moreover concerned in a number of processes requiring translation corresponding to germline formation, long run habituation and circadian rhythm formation. Nevertheless, it has but to be unambiguously demonstrated that Ataxin-2 is definitely concerned in activating the interpretation of its goal mRNAs. Right here we offer direct proof from a polysome profile evaluation displaying that Ataxin-2 enhances translation of goal mRNAs.
Our lately established technique for transcriptional pulse-chase evaluation beneath situations of suppressing deadenylation revealed that Ataxin-2 promotes post-transcriptional polyadenylation of the goal mRNAs. Moreover, Ataxin-2 binds to a poly(A) binding protein PABPC1 and a noncanonical poly(A) polymerase PAPD4 by way of its intrinsically disordered area (906-1095 aa) to recruit PAPD4 to the targets. Posttranscriptional polyadenylation by Ataxin-2 explains not solely the way it prompts translation but additionally stabilizes goal mRNAs, together with TDP-43 mRNA.
Ataxin-2 is thought to be a potent modifier of TDP-43 proteinopathies and to play a causative position within the neurodegenerative illness Spinocerebellar ataxia sort 2, so these findings recommend that Ataxin-2-induced cytoplasmic polyadenylation and activation of translation would possibly influence neurodegeneration (i.e., TDP-43 proteinopathies) and this course of may very well be a therapeutic goal for Ataxin-2-related neurodegenerative issues.
Machado-Joseph Deubiquitinases: From Mobile Capabilities to Potential Remedy Targets
Ubiquitination is named necessary post-translational modification in cancer-related pathways. Human deubiquitinases (DUBs), with capabilities of modulating the ubiquitination course of, are a household with about 100 proteins. They primarily operate by slicing ubiquitin chains of the substrates. The Machado-Joseph domain-containing proteases (MJDs) is among the sub-families of DUBs, consisting of 4 members, particularly, Ataxin-3, Ataxin-3L, JOSD1, and JOSD2. Latest research have supplied new insights into organic capabilities of MJDs within the development of Machado-Joseph illness or most cancers illnesses. On this assessment, we summarized the mobile capabilities and regulatory mechanisms of MJDs in Machado-Joseph illness and most cancers pathways.
Moreover, we summarized MJDs genetic alterations in numerous human cancers by exploring the general public databases (cBioportal). The purpose of this assessment is to supply a complete account primarily based on our present data about rising insights into MJDs in physiology and illness, which could make clear basic organic questions and promise to supply a possible goal for therapeutic intervention. The panorama of polyQ SCAs therapeutic targets and methods contains (1) the mutant genes and proteins themselves, (2) enhancement of endogenous protein high quality management responses, (3) irregular protein-protein interactions of the mutant proteins, (4) disturbed neuronal operate, (5) mitochondrial operate, power availability and oxidative stress, and (6) glial dysfunction, development issue or hormone imbalances.
Challenges embrace gaining a clearer definition of therapeutic targets for the medication in scientific improvement, the invention of novel drug-like molecules for difficult key targets, and the attainment of a stronger translation of preclinical findings to the clinic.
Direct evidence that Ataxin-2 is a translational activator mediating cytoplasmic polyadenylation
Main Enhancements in Robustness and Effectivity through the Screening of Novel Enzyme Effectors by the 3-Level Kinetics Assay
The throughput stage presently reached by computerized liquid dealing with and assay monitoring strategies is anticipated to facilitate the invention of recent modulators of enzyme exercise. Even handed and reliable methods to interpret huge quantities of knowledge are, nonetheless, required to successfully reply this problem. Right here, the 3-point technique of kinetic evaluation is proposed as a method to considerably improve the hit success charges and reduce the variety of falsely recognized compounds (false positives). On this post-Michaelis-Menten strategy, every screened response is probed in three completely different events, none of which essentially coincide with the preliminary interval of fixed velocity.
Enzymology rules somewhat than subjective standards are utilized to establish undesirable outliers corresponding to assay artifacts, after which to precisely distinguish true enzyme modulation results from false positives. The exclusion and choice standards are outlined primarily based on the 3-point response coordinates, whose relative positions alongside the time-courses might change from properly to properly or from plate to plate, if mandatory. The robustness and effectivity of the brand new technique is illustrated throughout a small drug repurposing screening of potential modulators of the deubiquinating exercise of ataxin-3, a protein implicated in Machado-Joseph illness. Apparently, intractable Z components are drastically enhanced after (1) eliminating spurious outcomes, (2) enhancing the normalization technique, and (3) growing the assay resilience to systematic and random variability. Numerical simulations additional show that the 3-point evaluation is very delicate to particular, catalytic, and slow-onset modulation results which are significantly troublesome to detect by typical endpoint assays.
Ataxin-3 Human Recombinant |
|||
| rAP-4434 | Angio Proteomie | Inquiry | Ask for price |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| CSB-EP002443HU | Cusabio | 11921 mg | Ask for price |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| CSB-EP002443HU-100ug | Cusabio | 100ug | Ask for price |
|
Description: 1-364aa |
|||
Recombinant Human Ataxin-3 (ATXN3) |
|||
| CSB-EP002443HU-1mg | Cusabio | 1mg | Ask for price |
|
Description: 1-364aa |
|||
Recombinant Human Ataxin-3 (ATXN3) |
|||
| CSB-EP002443HU-20ug | Cusabio | 20ug | Ask for price |
|
Description: 1-364aa |
|||
Recombinant Human Ataxin-3 (ATXN3) |
|||
| MBS953525-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1240 |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| MBS953525-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 900 |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| MBS953525-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1030 |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| MBS953525-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1085 |
Recombinant Human Ataxin-3 (ATXN3) |
|||
| MBS953525-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1170 |
Recombinant Human Ataxin-3 Protein |
|||
| MBS556290-0002mg | MyBiosource | 0.002mg | EUR 220 |
Recombinant Human Ataxin-3 Protein |
|||
| MBS556290-001mg | MyBiosource | 0.01mg | EUR 320 |
Recombinant Human Ataxin-3 Protein |
|||
| MBS556290-5x001mg | MyBiosource | 5x0.01mg | EUR 1300 |
Human Ataxin 3 Recombinant Protein |
|||
| PROTP54252 | BosterBio | Regular: 10ug | EUR 250 |
|
Description: Human Ataxin 3 Recombinant Protein expressed in E. coli (non-tagged). Sequence domain: 1-370aa. Application(s): SDS-PAGE. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method). |
|||
Recombinant Human Ataxin-3(Q22)/ATXN3 protein |
|||
| RP10099LQ | Abclonal | 50μg | EUR 230.26 |
Recombinant Human Ataxin-10 (ATXN10) |
|||
| MBS1317413-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1340 |
Recombinant Human Ataxin-10 (ATXN10) |
|||
| MBS1317413-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 1035 |
Recombinant Human Ataxin-10 (ATXN10) |
|||
| MBS1317413-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1135 |
Recombinant Human Ataxin-10 (ATXN10) |
|||
| MBS1317413-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1210 |
Recombinant Human Ataxin-10 (ATXN10) |
|||
| MBS1317413-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1295 |
Recombinant Human Ataxin-8 (ATXN8) |
|||
| MBS1425993-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1005 |
Recombinant Human Ataxin-8 (ATXN8) |
|||
| MBS1425993-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 570 |
Recombinant Human Ataxin-8 (ATXN8) |
|||
| MBS1425993-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 755 |
Recombinant Human Ataxin-8 (ATXN8) |
|||
| MBS1425993-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 680 |
Recombinant Human Ataxin-8 (ATXN8) |
|||
| MBS1425993-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 885 |
Recombinant Human Ataxin-3/ATXN3 protein (His tag) |
|||
| MBS2570912-002mg | MyBiosource | 0.02mg | EUR 135 |
Recombinant Human Ataxin-3/ATXN3 protein (His tag) |
|||
| MBS2570912-01mg | MyBiosource | 0.1mg | EUR 170 |
Recombinant Human Ataxin-3/ATXN3 protein (His tag) |
|||
| MBS2570912-5x01mg | MyBiosource | 5x0.1mg | EUR 765 |
Recombinant Human Ataxin-3/ATXN3 protein (His tag) |
|||
| PDEH100314-100ug | Elabscience Biotech | 100ug | EUR 118 |
|
Description: Human |
|||
Recombinant Human Ataxin-3/ATXN3 protein (His tag) |
|||
| PDEH100314-20ug | Elabscience Biotech | 20ug | EUR 68 |
|
Description: Human |
|||
Ataxin 3 (ATXN3) (NM_004993) Human Recombinant Protein |
|||
| E45H35067M5 | EnoGene | 20 ug | EUR 785.42 |
Ataxin 3 (ATXN3) (NM_004993) Human Recombinant Protein |
|||
| E45H32533I5 | EnoGene | 20 ug | EUR 1088.75 |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| CSB-EP613538HU | Cusabio | 11059 mg | Ask for price |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| CSB-EP613538HU-100ug | Cusabio | 100ug | Ask for price |
|
Description: 1-347aa |
|||
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| CSB-EP613538HU-1mg | Cusabio | 1mg | Ask for price |
|
Description: 1-347aa |
|||
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| CSB-EP613538HU-20ug | Cusabio | 20ug | Ask for price |
|
Description: 1-347aa |
|||
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| MBS1326731-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1230 |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| MBS1326731-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 885 |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| MBS1326731-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1020 |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| MBS1326731-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1065 |
Recombinant Human Ataxin-7-like protein 3 (ATXN7L3) |
|||
| MBS1326731-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1160 |
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-YP002445HU | Cusabio | 8043 mg | Ask for price |
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-YP002445HU-100ug | Cusabio | 100ug | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-YP002445HU-1mg | Cusabio | 1mg | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-YP002445HU-20ug | Cusabio | 20ug | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-2 (ATXN2), partial |
|||
| CSB-EP859520HU | Cusabio | 9027 mg | Ask for price |
Recombinant Human Ataxin-2 (ATXN2), partial |
|||
| CSB-EP859520HU-100ug | Cusabio | 100ug | Ask for price |
|
Description: 481-775aa |
|||
Recombinant Human Ataxin-2 (ATXN2), partial |
|||
| CSB-EP859520HU-1mg | Cusabio | 1mg | Ask for price |
|
Description: 481-775aa |
|||
Recombinant Human Ataxin-2 (ATXN2), partial |
|||
| CSB-EP859520HU-20ug | Cusabio | 20ug | Ask for price |
|
Description: 481-775aa |
|||
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-EP002445HU | Cusabio | 7218 mg | Ask for price |
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-EP002445HU-100ug | Cusabio | 100ug | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-EP002445HU-1mg | Cusabio | 1mg | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-7 (ATXN7), partial |
|||
| CSB-EP002445HU-20ug | Cusabio | 20ug | Ask for price |
|
Description: 79-401aa |
|||
Recombinant Human Ataxin-7 (ATXN7) , partial |
|||
| MBS1219994-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 320 |
Recombinant Human Ataxin-7 (ATXN7) , partial |
|||
| MBS1219994-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 360 |
Recombinant Human Ataxin-7 (ATXN7) , partial |
|||
| MBS1219994-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 520 |
Recombinant Human Ataxin-7 (ATXN7) , partial |
|||
| MBS1219994-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 610 |
Recombinant Human Ataxin-7 (ATXN7) , partial |
|||
| MBS1219994-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1925 |
Recombinant Human Ataxin-2 (ATXN2) , partial |
|||
| MBS1411583-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1170 |
Recombinant Human Ataxin-2 (ATXN2) , partial |
|||
| MBS1411583-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 320 |
Recombinant Human Ataxin-2 (ATXN2) , partial |
|||
| MBS1411583-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 960 |
Recombinant Human Ataxin-2 (ATXN2) , partial |
|||
| MBS1411583-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 520 |
Recombinant Human Ataxin-2 (ATXN2) , partial |
|||
| MBS1411583-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1125 |
Recombinant Human Ataxin-1-like (ATXN1L) |
|||
| MBS718671-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1540 |
Recombinant Human Ataxin-1-like (ATXN1L) |
|||
| MBS718671-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 1260 |
Recombinant Human Ataxin-1-like (ATXN1L) |
|||
| MBS718671-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1300 |
Recombinant Human Ataxin-1-like (ATXN1L) |
|||
| MBS718671-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1520 |
Recombinant Human Ataxin-1-like (ATXN1L) |
|||
| MBS718671-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1530 |
Recombinant Human Ataxin-1 (ATXN1) , partial |
|||
| MBS951962-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Recombinant Human Ataxin-7 (ATXN7) ,partial |
|||
| RPC28479-100ug | Biomatik Corporation | 100ug | EUR 635.8 |
Recombinant Human Ataxin-7 (ATXN7) ,partial |
|||
| RPC28479-1mg | Biomatik Corporation | 1mg | EUR 2885.2 |
Recombinant Human Ataxin-7 (ATXN7) ,partial |
|||
| RPC28479-20ug | Biomatik Corporation | 20ug | EUR 353.4 |
Recombinant Human Putative ataxin-3-like protein (ATXN3L) |
|||
| MBS1324675-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1230 |
Recombinant Human Putative ataxin-3-like protein (ATXN3L) |
|||
| MBS1324675-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 890 |
Recombinant Human Putative ataxin-3-like protein (ATXN3L) |
|||
| MBS1324675-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1020 |
Recombinant Human Putative ataxin-3-like protein (ATXN3L) |
|||
| MBS1324675-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1070 |
Recombinant Human Putative ataxin-3-like protein (ATXN3L) |
|||
| MBS1324675-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1160 |
Recombinant Ataxin 3 (ATXN3) |
|||
| RPD250Hu01 | Cloud-Clone | 10ug | EUR 120 |
Recombinant Rat Ataxin-3 (Atxn3) |
|||
| MBS1243203-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1230 |
Recombinant Rat Ataxin-3 (Atxn3) |
|||
| MBS1243203-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 890 |
Recombinant Rat Ataxin-3 (Atxn3) |
|||
| MBS1243203-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1020 |
Recombinant Rat Ataxin-3 (Atxn3) |
|||
| MBS1243203-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1070 |
Recombinant Rat Ataxin-3 (Atxn3) |
|||
| MBS1243203-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1160 |
Recombinant Mouse Ataxin-3 (Atxn3) |
|||
| MBS1457204-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1230 |
Recombinant Mouse Ataxin-3 (Atxn3) |
|||
| MBS1457204-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 890 |
Recombinant Mouse Ataxin-3 (Atxn3) |
|||
| MBS1457204-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1020 |
Recombinant Mouse Ataxin-3 (Atxn3) |
|||
| MBS1457204-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1070 |
Recombinant Mouse Ataxin-3 (Atxn3) |
|||
| MBS1457204-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1160 |
Recombinant Chicken Ataxin-3 (ATXN3) |
|||
| MBS1475975-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1235 |
Recombinant Chicken Ataxin-3 (ATXN3) |
|||
| MBS1475975-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 900 |
Recombinant Chicken Ataxin-3 (ATXN3) |
|||
| MBS1475975-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1030 |
Recombinant Chicken Ataxin-3 (ATXN3) |
|||
| MBS1475975-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1080 |
Recombinant Chicken Ataxin-3 (ATXN3) |
|||
| MBS1475975-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1170 |
Ataxin 3 Recombinant Rabbit mAb |
|||
| BS46593 | Bioworld Biotech | 50 ul | EUR 398 |
|
Description: Store at -20°C. Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt. |
|||
Recombinant Human Ataxin-7-like protein 2 (ATXN7L2) |
|||
| MBS1289577-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1570 |
Recombinant Human Ataxin-7-like protein 2 (ATXN7L2) |
|||
| MBS1289577-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 1300 |
Recombinant Human Ataxin-7-like protein 2 (ATXN7L2) |
|||
| MBS1289577-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1335 |
Recombinant Human Ataxin-7-like protein 2 (ATXN7L2) |
|||
| MBS1289577-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1565 |
Recombinant Human Ataxin-7-like protein 2 (ATXN7L2) |
|||
| MBS1289577-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1565 |
Ataxin 1 (ATXN1) (NM_001128164) Human Recombinant Protein |
|||
| E45H33460M5 | EnoGene | 20 ug | EUR 785.42 |
Ataxin 1 (ATXN1) (NM_000332) Human Recombinant Protein |
|||
| E45H34117M5 | EnoGene | 20 ug | EUR 785.42 |
Recombinant Human Ataxin-2-like protein (ATXN2L) , partial |
|||
| MBS1408189-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 940 |
Recombinant Human Ataxin-2-like protein (ATXN2L) , partial |
|||
| MBS1408189-005mgEColi | MyBiosource | 0.05mg(E-Coli) | EUR 580 |
Recombinant Human Ataxin-2-like protein (ATXN2L) , partial |
|||
| MBS1408189-005mgYeast | MyBiosource | 0.05mg(Yeast) | EUR 765 |
Recombinant Human Ataxin-2-like protein (ATXN2L) , partial |
|||
| MBS1408189-02mgEColi | MyBiosource | 0.2mg(E-Coli) | EUR 750 |
Recombinant Human Ataxin-2-like protein (ATXN2L) , partial |
|||
| MBS1408189-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 825 |
Ataxin 2 like (ATXN2L) (NM_148414) Human Recombinant Protein |
|||
| E45H35385M5 | EnoGene | 20 ug | EUR 785.42 |
Recombinant Human Ataxin-7-like protein 1 (ATXN7L1) , partial |
|||
| MBS1465659-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Recombinant Human Putative ataxin-7-like protein 3B (ATXN7L3B) |
|||
| MBS1285522-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1020 |
Recombinant Human Putative ataxin-7-like protein 3B (ATXN7L3B) |
|||
| MBS1285522-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 590 |
Recombinant Human Putative ataxin-7-like protein 3B (ATXN7L3B) |
|||
| MBS1285522-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 775 |
Recombinant Human Putative ataxin-7-like protein 3B (ATXN7L3B) |
|||
| MBS1285522-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 705 |
Recombinant Human Putative ataxin-7-like protein 3B (ATXN7L3B) |
|||
| MBS1285522-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 905 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2029964-001mg | MyBiosource | 0.01mg | EUR 175 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2029964-005mg | MyBiosource | 0.05mg | EUR 320 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2029964-01mg | MyBiosource | 0.1mg | EUR 490 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2029964-02mg | MyBiosource | 0.2mg | EUR 595 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2029964-05mg | MyBiosource | 0.5mg | EUR 1130 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2018515-001mg | MyBiosource | 0.01mg | EUR 170 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2018515-005mg | MyBiosource | 0.05mg | EUR 300 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2018515-01mg | MyBiosource | 0.1mg | EUR 450 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2018515-02mg | MyBiosource | 0.2mg | EUR 550 |
Recombinant Ataxin 1 (ATXN1) |
|||
| MBS2018515-05mg | MyBiosource | 0.5mg | EUR 1050 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU54042-100ug | Biomatik Corporation | 100ug | EUR 576.4 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU54042-1mg | Biomatik Corporation | 1mg | EUR 2555.8 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU54042-50ug | Biomatik Corporation | 50ug | EUR 463.1 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU40398-100ug | Biomatik Corporation | 100ug | EUR 530.2 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU40398-1mg | Biomatik Corporation | 1mg | EUR 2347.8 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPU40398-50ug | Biomatik Corporation | 50ug | EUR 425.7 |
Recombinant Ataxin 1 (ATXN1) |
|||
| RPA514Hu01 | Cloud-Clone | 10ug | EUR 172 |
Recombinant Ataxin 1 (ATXN1) |
|||
| 4-RPA514Hu01 | Cloud-Clone |
|
|
|
Description: Recombinant Human Ataxin 1 expressed in: E.coli |
|||
Recombinant Ataxin 1 (ATXN1) |
|||
| RPA514Mu01 | Cloud-Clone | 10ug | EUR 187 |
Recombinant Ataxin 1 (ATXN1) |
|||
| 4-RPA514Mu01 | Cloud-Clone |
|
|
|
Description: Recombinant Mouse Ataxin 1 expressed in: E.coli |
|||
Recombinant Rat Ataxin-10 (Atxn10) |
|||
| MBS1316499-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1340 |
Recombinant Rat Ataxin-10 (Atxn10) |
|||
| MBS1316499-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 1035 |
Recombinant Rat Ataxin-10 (Atxn10) |
|||
| MBS1316499-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 1135 |
Recombinant Rat Ataxin-10 (Atxn10) |
|||
| MBS1316499-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 1210 |
Recombinant Rat Ataxin-10 (Atxn10) |
|||
| MBS1316499-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1295 |
Recombinant Ataxin 10 (ATXN10) |
|||
| MBS2030435-001mg | MyBiosource | 0.01mg | EUR 170 |
Recombinant Ataxin 10 (ATXN10) |
|||
| MBS2030435-005mg | MyBiosource | 0.05mg | EUR 300 |
Recombinant Ataxin 10 (ATXN10) |
|||
| MBS2030435-01mg | MyBiosource | 0.1mg | EUR 450 |
Recombinant Ataxin 10 (ATXN10) |
|||
| MBS2030435-02mg | MyBiosource | 0.2mg | EUR 550 |
Recombinant Ataxin 10 (ATXN10) |
|||
| MBS2030435-05mg | MyBiosource | 0.5mg | EUR 1050 |
Recombinant Ataxin 10 (ATXN10) |
|||
| RPU52663-100ug | Biomatik Corporation | 100ug | EUR 530.2 |
Recombinant Ataxin 10 (ATXN10) |
|||
| RPU52663-1mg | Biomatik Corporation | 1mg | EUR 2347.8 |
Recombinant Ataxin 10 (ATXN10) |
|||
| RPU52663-50ug | Biomatik Corporation | 50ug | EUR 425.7 |
Though attributable to an analogous mutation, polyglutamine issues are distinct, implicating non-polyglutamine areas of illness proteins as regulators of pathogenesis. SCA3 is attributable to polyglutamine enlargement in ataxin-3. To find out the position of ataxin-3’s non-polyglutamine domains in illness, we utilized a brand new, allelic collection of Drosophila melanogaster.